PHARNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pharming Group N.V.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 2, 2026
$9.11−0.25 (-2.67%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 2277.5
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
87.9%−1.0 pts over 5 years
Operating margin
6.9%−29.1 pts over 5 years
Net margin
0.8%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +26.6% | +22.3% | +12.1% | – | |
| Gross profit | +26.3% | +20.7% | +11.9% | – | |
| Operating income | – | +12.3% | -19.5% | – | |
| EPS, diluted | – | -40.5% | -40.8% | – | |
| Free cash flow | – | +36.8% | -7.3% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | – | – | 0.6% | |
| Current ratio | – | 3.43 | 2.59 | |
| Interest coverage | – | 1030.5× | 131.8× | |
| Inventory turnover | – | 1.3× | 0.8× | |
| Capex to revenue | – | 2.2% | 0.2% | |
| Diluted shares | 654M | 683M | 747M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Pharming generated $134.11M from operations and spent $15.09M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$134.11M
Used
$15.09M
Capital expenditure$15.09M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$2.85M
- Cash generatingOperating cash flow above zero$54.71M
- Return on assets improvedROA up on the prior year-2.6% → 0.7%
- Earnings backed by cashOperating cash flow above net income$54.71M vs $2.85M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.77 → 2.59
- No dilutionShare count did not rise785M → 747M
- Gross margin improvedGross margin up on the prior year88.09% → 87.90%
- More efficientAsset turnover rose0.64 → 0.94